Trial | Total sample size | Sex | Age (yrs) | Weight (kg) | Baseline VO2peak (ml/kg/min) | NO3− dose (mmol/day) | NO3− dose (mmol/kg/day)* | Acute dose prior | Health status | Route of administration |
---|---|---|---|---|---|---|---|---|---|---|
De Smet et al. [28] | 17 | M | 24.5 | 79.0 | 52.8 | 6.5 | 0.082 | No | Healthy | BRJ |
Finkel et al. [29] | 16 | M | 26.7 | 77.9 | 56.7 | – | 0.140 | No | Healthy | Other |
Muggeridge et al. [30] | 19 | M | 28.5 | 82.3 | 41.0 | 8.0 | 0.097 | No | Healthy | Other |
Puype et al. [31] | 22 | M | 21.6 | 72.2 | 60.5 | 11.3 | 0.070 | Yes | Healthy | BRJ |
Shaltout et al. [32a] | 19 | M/F | 69.3 | 87.8 | 11.9 | 6.1 | 0.069 | Yes | Clinical | BRJ |
Shaltout et al. [32b] | 27 | M/F | 65.3 | 97.8 | 18.4 | 8.0 | 0.082 | Yes | Clinical | BRJ |
Sousa et al. [33] | 20 | M | 36.8 | 70.6 | 56.2 | 8.4 | 0.120 | Yes | Healthy | BRJ |
Thompson et al. [34] | 24 | M/F | 25.0 | 72.5 | 45.1 | 12.8 | 0.180 | Yes | Healthy | BRJ |
Thompson et al. [35a] | 24 | M/F | 23.5 | 75.5 | 43.3 | 12.8 | 0.170 | Yes | Healthy | BRJ |
Thompson et al. [35b] | 24 | M/F | 23.5 | 75.5 | 43.3 | 12.8 | 0.170 | Yes | Healthy | Other |
Woessner et al. [36] | 24 | M/F | 69.7 | 80.5 | 14.7 | 4.2 | 0.050 | No | Clinical | BRJ |